Attitudes and treatment outcome of breast conservation therapy for stage I & II breast cancer using peroperative iridium-192 implant boost to the tumour bed

Australas Radiol. 2001 Feb;45(1):35-8. doi: 10.1046/j.1440-1673.2001.00870.x.

Abstract

Breast conservation therapy for early breast cancer is an established but grossly under-utilized treatment option in India for various reasons. Breast conservation therapy was offered to 200 suitable breast cancer patients between June 1993 and June 1998. Fifty-one patients (25%) opted for breast conservation and the remaining preferred mastectomy. In patients agreeing to conservation therapy, surgery was performed first along with peroperative implantation of iridium-192 to deliver a boost. Whole breast irradiation of 45 Gy was delivered 3-4 weeks after the boost. Cosmesis was assessed at the end of 6 months from completion of therapy. The main reason for refusal of breast conservation therapy was fear of recurrence in the remaining breast (60%). There were no locoregional failures in our study at a median follow up of 42 months; one patient experienced a systemic relapse. Cosmesis was good to excellent in 80% of patients. Breast conservation therapy using peroperative iridium-192 implant provides excellent locoregional disease control and cosmesis. The results of our study indicate that patient preference for mastectomy is an important reason for the under-utilization of breast conservation therapy in India.

MeSH terms

  • Adult
  • Brachytherapy / instrumentation*
  • Breast Neoplasms / radiotherapy*
  • Breast Neoplasms / surgery
  • Female
  • Health Knowledge, Attitudes, Practice*
  • Humans
  • India
  • Iridium Radioisotopes / therapeutic use*
  • Middle Aged
  • Preoperative Care
  • Radiotherapy Dosage
  • Treatment Outcome

Substances

  • Iridium Radioisotopes